Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | METAP2 | P50579 | 2/20 | 0.47 |
| ▸ | METAP1 | P53582 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | COMT | P21964 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.47 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28117700 | 0.81 | MAPT (0.49) | PARP1TSHRMMP2METAP2METAP1 | |
| SCHEMBL16084043 | 0.80 | MMP2 (0.55) | PARP1TSHRMMP2METAP2METAP1 | |
| SCHEMBL17541529 | 0.77 | MMP2 (0.52) | PARP1TSHRMMP2METAP2METAP1 | |
| SCHEMBL19682364 | 0.76 | PARP1 (0.46) | PARP1TSHRMMP2METAP2METAP1 | |
| SCHEMBL20889269 | 0.76 | PARP1 (0.46) | PARP1TSHRMMP2METAP2METAP1 | |
| SCHEMBL28010277 | 0.76 | LMNA (0.50) | PARP1TSHRMMP2METAP2METAP1 | |
| SCHEMBL3639223 | 0.75 | P2RX7 (0.42) | KDM4ELMNATDP1 | |
| SCHEMBL25108902 | 0.75 | ALDH1A1 (0.47) | ALDH1A1KDM4ELMNAMAPTSMN1; SMN2 | |
| SCHEMBL5185814 | 0.75 | PARP1 (0.47) | PARP1TSHRMMP2METAP2METAP1 | |
| SCHEMBL1837396 | 0.74 | KDM4E (0.53) | TSHRMETAP2METAP1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0626958-A1 | SULFONYLUREAS AS HERBICIDES | CIBA-GEIGY AG (CH) | 1994-12-07 | — | — | EP | claimed |
| WO-1993017016-A1 | SULFONYLUREAS AS HERBICIDES | CIBA-GEIGY AG (CH) | 1993-09-02 | — | — | WO | claimed |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| CN-112087950-B | Use of safeners for increasing the resistance of rice crops to herbicides | 安道麦阿甘有限公司 | 2023-02-28 | — | — | CN | disclosed |
| US-5756422-A | PLANT SAFENING AGENTS | HOECHST SCHERING AGREVO GMBH (DE) | 1998-05-26 | — | — | US | disclosed |
| EP-0626958-A1 | SULFONYLUREAS AS HERBICIDES | CIBA-GEIGY AG (CH) | 1994-12-07 | — | — | EP | disclosed |
| WO-1993017016-A1 | SULFONYLUREAS AS HERBICIDES | CIBA-GEIGY AG (CH) | 1993-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | USP9X, USP19, USP39 | PARP1 1678/4885TSHR 4189/4885MMP2 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.